Blog
The Path to Healthy Aging: What Longevity Medicine Can Do for Someone in Their 60s and 70s
Most of the conversations people in their sixties have with their doctors follow the same arc. Cholesterol slightly up. Blood pressure at the high end. Blood sugar creeping. The doctor adjusts a statin, recommends more exercise, and schedules a follow-up in twelve months. This is aging management, and it’s fundamentally different than optimization. Management says: keep the numbers from getting worse. Longevity medicine asks: what does “better” actually look like, and what’s the path to healthy aging?
For a growing number of people in their sixties and seventies, the distinction matters enormously. Not because they’re sick, but because they’ve decided they’re not interested in spending the next twenty years on a managed decline curve.
Standard Care vs. Longevity Medicine
Primary care medicine is built around disease detection and risk management. It’s exceptionally good at identifying when something has gone wrong and intervening to prevent it from getting worse. Annual physicals, standard lipid panels, blood pressure monitoring, diabetes screening — these are population-level tools designed to catch conditions before they become catastrophic.
What they’re not designed to do is optimize. They’re not looking for the difference between testosterone at the bottom of the normal range and testosterone at the top. They’re not measuring intracellular NAD+. They’re not assessing biological age or tracking the gap between how old you are and how old your cells are.
Standard care defines success as “nothing is wrong.” Longevity medicine defines success as “everything is working at the level you need it to.”
For most people in their sixties, both are true simultaneously: nothing is catastrophically wrong, and nothing is working quite as well as it could be.
Evidence-Based Longevity Therapies at LIVV
This is where the conversation often gets muddled by skepticism on one end and overstatement on the other. Longevity medicine isn’t magic. It’s a set of evidence-based interventions that address the specific biological mechanisms of aging — mitochondrial decline, hormonal depletion, systemic inflammation, cellular senescence, and neurological aging.
Here’s what the research actually supports for people in their sixties and seventies:
Hormone Optimization
Testosterone levels in men decline approximately 1–2% per year from the mid-thirties onward. By sixty-five, a man may have forty to fifty percent less circulating testosterone than he did at his peak. The clinical effects — fatigue, muscle loss, cognitive decline, metabolic drift, increased cardiovascular risk — are well-documented.
Testosterone replacement therapy in physiological doses (restoring levels to the upper-normal range for age, not supraphysiological) has strong evidence for:
- Lean muscle preservation and improved body composition
- Reduced cardiometabolic risk markers
- Improved cognitive function and mood
- Bone density maintenance
- Energy and motivation restoration
For women, bioidentical HRT addresses the hormonal depletion of menopause with evidence for cardiovascular protection, cognitive preservation, bone health, and quality of life — particularly when initiated within ten years of menopause onset.
Peptide Therapy
Peptides are short amino acid sequences that signal specific biological processes. Several have strong evidence for the conditions most relevant to people in their sixties and seventies:
CJC-1295/Ipamorelin — stimulates the body’s natural growth hormone pulse during sleep, supporting lean muscle preservation, tissue repair, sleep quality, and metabolic function. Not growth hormone replacement — GH axis stimulation, which preserves the natural feedback mechanisms.
Epithalon — a tetrapeptide with research supporting telomere elongation and cellular longevity. Extensively studied for anti-aging applications with evidence for circadian rhythm normalization and biological age correction.
BPC-157 — strong evidence for tissue repair, anti-inflammation, and joint integrity. For the chronic joint pain and slower healing that commonly accompanies aging, one of the most directly applicable interventions available.
Cerebrolysin and Semax — neuroprotective peptides with published evidence for cognitive protection, BDNF support, and neurological aging mitigation. These aren’t experimental; Cerebrolysin has been used clinically for neurological conditions for decades.
NAD+ Restoration
NAD+ (nicotinamide adenine dinucleotide) is the coenzyme that drives mitochondrial energy production and DNA repair. Its levels decline approximately fifty percent between age forty and sixty, and continue declining. This decline is directly implicated in the fatigue, cognitive slowdown, and accelerated cellular aging that characterize the decades after sixty.
IV NAD+ infusions or injections deliver the compound directly into the bloodstream at the intracellular concentration that oral supplementation frequently fails to achieve. The evidence for energy restoration, cognitive function improvement, and mitochondrial efficiency is consistent and growing.
Regenerative Therapies
Stem Cell IV — uses extracellular vesicles derived from stem cells to signal cellular repair and immune modulation throughout the body. Evidence is still accumulating, but consistent findings include systemic inflammation reduction, immune system rebalancing, and tissue repair enhancement. For individuals with a significant biological age gap, this is one of the highest-impact interventions available.
HBOT (Hyperbaric Oxygen Therapy) — delivers oxygen to tissues at elevated atmospheric pressure, dramatically increasing cellular oxygen availability. For people in their sixties and seventies, evidence spans cardiovascular tissue health, brain health (including cognitive performance and neurogenesis), wound and tissue healing, and systemic inflammation reduction. A 2020 study in Aging demonstrated that HBOT protocols in healthy aging adults produced significant telomere elongation and reduction in senescent cell burden.
PRP (Platelet-Rich Plasma) — for the joint pain and mobility limitations that frequently constrain activity in this age group, PRP delivers concentrated growth factors directly to compromised joint structures, stimulating biological repair rather than just masking symptoms.
The Biological Age Question
One of the most significant developments in longevity medicine over the last decade is the ability to measure biological age separately from chronological age. Epigenetic methylation testing, telomere length analysis, and composite biological age algorithms give a quantitative answer to the question: how old is your body, versus how old are you?
For many people in their sixties, these tests reveal a gap — biological age tracking five, eight, or ten years ahead of chronological age. This isn’t a life sentence. It’s a target. And it’s measurable.
Protocols built around closing that gap — reducing it, tracking it quarterly, and adjusting interventions based on how biology is actually responding — represent the difference between aging and optimizing how aging happens.
Longevity Protocols at LIVV Cardiff
LIVV members in their sixties and seventies who are on a longevity protocol don’t describe it as treatment. They describe it as getting their options back.
The knee that was heading toward replacement surgery holding steady — or improving. The cognitive performance that was quietly slipping, stabilizing and then recovering. The energy that had become a rationed resource becoming available again. The physical capability to stay active, present, and independent — not just for the next few years, but for the next two decades.
Managing aging means keeping the numbers from getting worse.
Changing it means deciding what “better” looks like — and having the tools to get there.